Thomas Schmidt, MD
Enriched profileRheumatology physician, Iowa Arthritis and Osteoporosis Center · Iowa Arthritis and Osteoporosis Center
Thomas Schmidt is Rheumatology physician, Iowa Arthritis and Osteoporosis Center at Iowa Arthritis and Osteoporosis Center. ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 3 Nov 2026
Overview
Updated 3 Nov 2026
Thomas Schmidt, MD, is Rheumatology physician, Iowa Arthritis and Osteoporosis Center. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 3 companies, 2 NIH-funded awards (1985–1986).
- Top research focus: Rheumatology/Immunology
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 3 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 3 Nov 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
Industry payments
Updated 3 Nov 2026
3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- GlaxoSmithKline, LLC.Program year20231 payment
- Novartis Pharmaceuticals CorporationProgram year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
71.2%Interleukin-6 Receptor Antagonist44.8%Tocilizumab100%Actemra0%Part D + Part B<11 patientsTNF inhibitor20.1%Certolizumab pegol49%Golimumab37%Infliximab13%Humira(Cf) Pen1%Humira(Cf)0%Enbrel Sureclick0%Enbrel0%Part D + Part B<11 patients+ 6 more classes in this area
Musculoskeletal
27%Other drugs affecting bone structure and mineralization19.4%Romosozumab-aqqg100%Part B, office-administered≥28 patientsRANK Ligand Inhibitor7%Denosumab100%Part B, office-administered≥81 patients+ 5 more classes in this area
Metabolism & gastrointestinal
0.5%Corticosteroid0.4%Prednisone100%Part D≥159 patientsAminosalicylate0.1%Sulfasalazine53%Sulfasalazine Dr47%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 3 Nov 2026
2 NIH research awards on record, funded 1985–1986 per NIH RePORTER. The latest:
- Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity
University of Pennsylvania
FY2026$667,593R01AI170137 - Using Disadvantage Indices in Pandemic Vaccine Allocation and Beyond to Promote Health Opportunity
University of Pennsylvania
FY2025$767,180R01AI170137
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Background & recognition
Updated 3 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.unitypoint.org ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Rheumatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →events.arthritis.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →events.arthritis.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine